Ranbaxy announces settlement of Imitrex litigation with GSK

7160 Investors following GlaxoSmithKline. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy announces settlement of Imitrex litigation with GSK

Ranbaxy Laboratories Limited (Ranbaxy) announced today that it has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex® Tablets.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy Labs leads gainers on the Sensex Ranbaxy a multi-bagger stock: Mukadam Ranbaxy Q4 net profit up at Rs 301.60 cr ALSO READ See latest News about GlaxoSmithKline See previous management interviews See what other Experts & Brokerages are saying about GlaxoSmithKline GlaxoSmithKline BSE | NSE 25/05/12 Are Mutual Funds betting on GlaxoSmithKline? Other Stocks in this news Ranbaxy Laboratories |

Ranbaxy Laboratories Limited (Ranbaxy) announced today that it has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex® Tablets.

The terms of the settlement, provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate Tablets (in the 25 mg,50 mg and 100 mg strengths) in the United States with an expected launch date in December, 2008.

Additional terms of the settlement agreement were not disclosed.

The annual market sales for Sumatriptan Succinate (Imitrex®) were USD 985 million (IMS- MAT: Sept 2007).

Sourced From: Ranbaxy Laboratories Ltd